Perfil de la empresa · Healthcare

Sino Biopharmaceutical Ltd

1177 · Hong Kong
País / Región
Hong Kong
Fecha de salida a bolsa
29 de septiembre de 2000
Empleados
22.838
Buffett Score
79/100
Sólida
Capitalización99,38 mil M HKD
Ingresos (TTM)33,7 mil M HKD
EBITDA10,45 mil M HKD
Margen neto7,09 %
ROE14,07 %
PER (TTM)37,2
PER previsto17,39
PEG0,72
BPA0,00 HKD
Rentabilidad por dividendo1,84 %
Rango de 52 semanas4,14 HKD – 8,33 HKD

Datos de EODHD, mostrados en la moneda de reporte; solo a título informativo, no constituye asesoramiento de inversión.

Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People's Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company offers oncology medicines, including anlotinib hydrochloride capsules under Focus V brand, penpulimab injection under Annike brand, efbemalenograstin alfa injection under Yilishu brand, benmelstobart injection under Andewei brand, unecritinib fumarate capsules under Anboni brand, envonalkib citrate capsule under Anluoqing brand, garsorasib tablets under Anfangning brand, bevacizumab injection under Anbeisi brand, culmerciclib capsule under Saitanxin brand, zongertinib tablets under Hernexeos brand, rovadicitinib tablet under Anxu brand,rituximab injection under Delituo brand, trastuzumab for injection under Saituo brand, and pertuzumab injection, under Paletan brand; liver disease medications, such as magnesium isoglycyrrhizinate injection under Tianqing Ganmei brand and entecavir dispersible tablets under Runzhong brand; and respiratory system medicines comprising budesonide suspension for inhalation under Tianqing suchang brand. It also provides surgery/analgesia medicines, including flurbiprofen cataplasms under the brand Zepolas, limaprost tablets under the brand Kailitong, and recombinant human coagulation factor VIII for injection under the brand Anqixin. In addition, the company develops liver disease drugs, such as Lanifibranor and TQA2225; respiratory system drugs comprising TDI01, TQC2731, TCR1672, TQC3721, and TQH3906; and surgery/analgesia drugs, including PL-5, an antimicrobial peptide, TRD205, an AT2R inhibitor, and TRD208. Further, it is involved in the long-term investments; and healthcare and hospital business. The company was incorporated in 2000 and is headquartered in Wan Chai, Hong Kong.

Historia

PróximamenteEsta sección se está completando; vuelve pronto.

Posición en el sector

PróximamenteEsta sección se está completando; vuelve pronto.

Aún no hay análisis sobre este valor en tu idioma.